|
| Advanced Cell Technology, Inc. | | | | Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Its embryonic stem cell research programs include cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company’s cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. Advanced Cell Technology, Inc. also generates stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The company’s stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. The company is headquartered in Marlborough, Massachusetts. | | | | Li3 Energy | | | | Li3 Energy, Inc. is a South American based global exploration and developmental stage public company in the lithium mining and energy sector. Li3 aims to acquire, develop and commercialize a significant portfolio of lithium brine deposits in the Americas. With its controlling interest in its Maricunga project (consisting of mining concessions covering an area of approximately 3,553 acres located in the Salar de Maricunga in northern Chile) and its other prospective strategic lithium and mineral holdings, Li3 Energy is focused on commercializing these assets in an accelerated manner by exploring the use of intensified evaporative and other advanced processing technologies. Li3's goals are to; a) support the global implementation of clean and green energy initiatives; b) meet growing lithium market demand and; c) become a mid-tier, low cost supplier of lithium, potassium nitrate, iodine and other strategic minerals, serving global clients in the energy, fertilizer and specialty chemical industries. Li3 is led by a management team of seasoned industry veterans with extensive exploration, mining, minerals, finance and commercialization expertise and a Board of Directors including global industry thought leaders who have advised, led and operated numerous mining entities. Additional information regarding the company can be found in our recent filings with the SEC as well as the information maintained on our website www.li3energy.com. | | | | AspenBio Pharma, Inc. | | | | AspenBio Pharma, Inc. operates as an emerging biomedical company focused on obtaining the United States FDA clearance for its lead product, AppyScore. Its research and development activities primarily focus on a human appendicitis blood-based test. The company’s lead product candidate, AppyScore, is a blood-based diagnostic test to help physicians manage patients who enter emergency rooms complaining of abdominal pain and suspected of having acute appendicitis. It is also developing animal healthcare products focusing on reproduction. The company was formerly known as AspenBio, Inc. and changed its name to AspenBio Pharma, Inc. on September 26, 2005. AspenBio Pharma, Inc. was founded in 2000 and is based in Castle Rock, Colorado. | | |
|
|